Research investigates the association between irritable bowel syndrome (IBS) and Parkinson's disease (PD), revealing that IBS is not linked to an increased overall risk of PD. Subgroup analyses suggest that certain IBS populations may have a lower risk of developing PD.
When patients with paroxysmal nocturnal hemoglobinuria (PNH) received eculizumab, survival rates increased and thromboembolic events/major adverse vascular events (TE/MAVE) decreased.